GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the appointment of Jon D. Isaacson as the company’s Chief Financial Officer, effective immediately. Concurrently, and as previously announced, R. Don Elsey has stepped down from the position and will continue in an advisory role to ensure an orderly transition and completion of the company’s annual SEC filings for the 2018 fiscal year.
“We are excited to welcome Jon to the Senseonics team. He brings a strong background of financial and operational success to the company at a pivotal time as we enter our next phase launching the Eversense system in the U.S.,” said Tim Goodnow, President and Chief Executive Officer. “His experience as an operator will be very valuable as we scale internally to support this launch. Again, we want to thank Don for his service and wish him well in the future.”
Mr. Isaacson has nearly 25 years of experience in financial leadership roles. Most recently he served as Chief Financial Officer of Edelman Financial Services where he was responsible for financial planning and analysis, tax, treasury and corporate development. Under his leadership, the company completed a transformative merger and a successful financing. As a member of the executive team, he was involved in all facets of the business. Prior to this role, Mr. Isaacson was a Managing Director at a private equity firm where he led the East Coast healthcare practice. There he led approximately $1 billion of transactions and investments in companies within the healthcare sector, and subsequently assumed advisory and board of directors’ roles with several healthcare companies. Mr. Isaacson holds a Masters of Business Administration from the Stanford Graduate School of Business and Bachelor of Arts from the Johns Hopkins University.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformative glucose monitoring products designed to help people with diabetes confidently live their lives with ease. From its inception, Senseonics has been advancing the integration of novel, fluorescence sensor technology with smart wearable devices. The Eversense® CGM System received PMA approval from the FDA for up to 90 days of continuous use and is available in the United States. The Eversense® CGM XL System received CE mark for up to 180 days of continuous use and is available in Europe. For more information on Senseonics, please visit www.senseonics.com.
Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects for Senseonics, including statements about the expanded commercialization of Eversense in Europe, the continuing launch in the U.S., and delivering life changing technology to people with diabetes, and other statements containing the words “expect,” “intend,” “may,” “projects,” “will,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties in the development and regulatory approval processes, uncertainties inherent in the commercial launch and commercial expansion of the product, and such other factors as are set forth in the risk factors detailed in Senseonics’ Annual Report on Form 10-K for the year ended December 31, 2017, Senseonics’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, and Senseonics’ other filings with the SEC under the heading “Risk Factors.” In addition, the forward-looking statements included in this press release represent Senseonics’ views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics’ views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics’ views as of any date subsequent to the date hereof.
